Lilly’s Taltz leads to durable improvement in axial spondyloarthritis in Phase 3 study

Eli Lilly and Company (NYSE:LLY) has announced that recent Phase 3 data suggest Taltz (ixekizumab) was effective in the long-term management of axial spondyloarthritis (axSpA). Taltz, an interleukin-17A antagonist, is currently indicated for plaque psoriasis, psoriatic arthritis and active ankylosing spondylitis.

In the COAST-Y study, Taltz demonstrated long-term improvements in patients’ symptoms with the two subtypes of axSpA. The first, known as radiographic axSpA (r-axSpA), involves defined structural damage of the sacroiliac joints evident on x-ray films. The second type, known as non-radiographic axSpA (nr-axSpA), lacks such structural damage.

The former can lead to substantial reductions in quality of life. “If left uncontrolled, individuals living with active radiographic axSpA can experience severe, chronic pain and structural damage in the spine that can lead to fusion of the spine and loss of mobility,” explained Dr. Walter P. Maksymowych, professor …

Read more
  • 0